| Cancer-related molecular mechanisms research | Lifetime | 48 | CN 18 | 99.68 |
| Cancer-related gene regulation | Lifetime | 26 | CN 2 | 99.75 |
| Epigenetics and DNA Methylation | Lifetime | 81 | CN 3 | 99.68 |
| Gut microbiota and health | Lifetime | 46 | CN 2 | 99.77 |
| Helicobacter pylori-related gastroenterology studies | Lifetime | 52 | CN 3 | 99.60 |
| RNA modifications and cancer | Lifetime | 190 | CN 16 | 99.48 |
| Liver Disease Diagnosis and Treatment | Lifetime | 256 | CN 10 | 99.59 |
| MicroRNA in disease regulation | Lifetime | 292 | CN 101 | 98.90 |
| Genetic factors in colorectal cancer | Lifetime | 358 | CN 3 | 98.63 |
| Cancer, Stress, Anesthesia, and Immune Response | Lifetime | 89 | CN 6 | 97.38 |
| Clostridium difficile and Clostridium perfringens research | Lifetime | 179 | CN 7 | 98.39 |
| Cancer, Lipids, and Metabolism | Lifetime | 371 | CN 8 | 98.53 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 648 | CN 14 | 98.54 |
| Ubiquitin and proteasome pathways | Lifetime | 487 | CN 39 | 97.85 |
| Wnt/β-catenin signaling in development and cancer | Lifetime | 184 | CN 7 | 97.52 |
| Circular RNAs in diseases | Lifetime | 414 | CN 218 | 97.43 |
| Cancer Research and Treatments | Lifetime | 567 | CN 30 | 97.17 |
| Inflammatory mediators and NSAID effects | Lifetime | 558 | CN 20 | 96.94 |
| Cancer Mechanisms and Therapy | Lifetime | 407 | CN 61 | 95.96 |
| Ferroptosis and cancer prognosis | Lifetime | 579 | CN 316 | 94.49 |
| Galectins and Cancer Biology | Lifetime | 492 | CN 10 | 95.48 |
| Hippo pathway signaling and YAP/TAZ | Lifetime | 209 | CN 16 | 95.91 |
| Kruppel-like factors research | Lifetime | 239 | CN 24 | 95.31 |
| Peroxisome Proliferator-Activated Receptors | Lifetime | 711 | CN 25 | 95.79 |
| Liver physiology and pathology | Lifetime | 611 | CN 46 | 95.59 |
| Autophagy in Disease and Therapy | Lifetime | 959 | CN 195 | 94.86 |
| Lipid metabolism and disorders | Lifetime | 724 | CN 30 | 93.21 |
| Veterinary medicine and infectious diseases | Lifetime | 946 | CN 48 | 87.32 |
| Andrographolide Research and Applications | Lifetime | 457 | CN 115 | 58.82 |
| Gut microbiota and health | 2021-2025 | 5 | CN 3 | 99.95 |
| Clostridium difficile and Clostridium perfringens research | 2021-2025 | 5 | CN 3 | 99.33 |
| RNA modifications and cancer | 2021-2025 | 38 | CN 26 | 99.55 |
| Liver Disease Diagnosis and Treatment | 2021-2025 | 189 | CN 16 | 99.02 |
| Diet and metabolism studies | 2021-2025 | 171 | CN 18 | 97.94 |
| Cancer-related gene regulation | 2021-2025 | 62 | CN 41 | 95.35 |
| Cancer-related molecular mechanisms research | 2021-2025 | 329 | CN 253 | 97.26 |
| Helicobacter pylori-related gastroenterology studies | 2021-2025 | 100 | CN 22 | 96.44 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 351 | CN 39 | 97.20 |
| Colorectal Cancer Screening and Detection | 2021-2025 | 228 | CN 23 | 95.97 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 446 | CN 84 | 96.43 |
| Digestive system and related health | 2021-2025 | 40 | CN 14 | 91.98 |
| Metabolomics and Mass Spectrometry Studies | 2021-2025 | 284 | CN 82 | 93.74 |
| Cancer, Stress, Anesthesia, and Immune Response | 2021-2025 | 64 | CN 19 | 89.21 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 415 | CN 153 | 90.51 |
| Ferroptosis and cancer prognosis | 2021-2025 | 720 | CN 611 | 91.63 |
| Endoplasmic Reticulum Stress and Disease | 2021-2025 | 247 | CN 55 | 86.62 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | 2021-2025 | 662 | CN 150 | 90.79 |
| Probiotics and Fermented Foods | 2021-2025 | 778 | CN 324 | 89.98 |
| Cancer Research and Treatments | 2021-2025 | 440 | CN 188 | 85.65 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 915 | CN 126 | 89.65 |
| Diet, Metabolism, and Disease | 2021-2025 | 614 | CN 113 | 86.15 |
| Mycobacterium research and diagnosis | 2021-2025 | 724 | CN 113 | 85.24 |
| Cancer Cells and Metastasis | 2021-2025 | 1,000 | CN 214 | 83.16 |
| Molecular Biology Techniques and Applications | 2021-2025 | 481 | CN 133 | 77.92 |
| Drug Transport and Resistance Mechanisms | 2021-2025 | 641 | CN 144 | 78.61 |
| Ginseng Biological Effects and Applications | 2021-2025 | 447 | CN 377 | 78.60 |
| Hippo pathway signaling and YAP/TAZ | 2021-2025 | 387 | CN 181 | 70.65 |
| Lipid metabolism and disorders | 2021-2025 | 913 | CN 280 | 60.30 |
| Cholesterol and Lipid Metabolism | 2021-2025 | 914 | CN 231 | 50.35 |
| Wnt/β-catenin signaling in development and cancer | 2021-2025 | 892 | CN 253 | 43.92 |
| FOXO transcription factor regulation | 2021-2025 | 473 | CN 170 | 29.61 |
